PacBio HiFi Genome Sequencing Services Tender, USA - 123895523

Procurement Summary

Country: USA

Summary: PacBio HiFi Genome Sequencing Services

Deadline: 14 Aug 2025

Other Information

Notice Type: Tender

TOT Ref.No.: 123895523

Document Ref. No.: NOI-NIAID-25-2261621

Financier: Self Financed

Purchaser Ownership: Public

Tender Value: Refer Document

Purchaser's Detail

Name: Login to see tender_details

Address: Login to see tender_details

Email: Login to see tender_details

Login to see details

Tender Details

Description

THIS IS A NOTICE OF INTENT AND NOT A REQUEST FOR QUOTATIONS

This notice is published in accordance with Federal Acquisition Regulation (FAR) 5.101(a)(1) requiring the dissemination of information regarding proposed contract actions. This is a Notice of Intent to award a sole source, firm-fixed price order under the authority of 41 U.S.C. 3304(a)(1), as implemented by FAR 6.302-1 - Only One Responsible Source and No Other Supplies or Service Will Satisfy Agency Requirements and is not a request for competitive proposals.

The National Institute of Allergy and Infectious Diseases (NIAID) intends to negotiate on a sole source basis with Infinity Biologix LLC dba Sampled, 30 Knightsbridge, Building 3, Piscataway, NJ 08854.

The National Institute of Allergy and Infectious Disease (NIAID) Division of Intramural Research (DIR) scientists study all aspects of infectious diseases, including the causative agent, vectors, and pathogenesis in human and animal hosts. Clinical research is an integral part of this mission, enabling key lab discoveries to be rapidly translated into methods to prevent, diagnose, or treat disease. DIR researchers annually conduct more than 200 clinical trials at the NIH Clinical Center on the Bethesda, Maryland, campus and at collaborating U.S. and international sites.

In support of clinical research, the NIAID Centralized Sequencing Program (CSP) is comprehensive program that obtains genetic testing, harmonizes phenotypic and genomic data, performs variant interpretation, and provides clinically validated results for patients enrolled in protocols at the NIH Clinical Center. The goal of the NIAID Centralized Sequencing Program is both to contribute to the understanding of underlying genetic etiology of disease and to address the clinical need for genomic evaluations.

The purpose of this acquisition is to obtain genetic testing for the NIAID Centralized Sequencing Program to support the mission of DIR. The objectiv...
Active Contract Opportunity
Notice ID : NOI-NIAID-25-2261621
Related Notice
Department/Ind. Agency : HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Sub-tier : NATIONAL INSTITUTES OF HEALTH
Office: NATIONAL INSTITUTES OF HEALTH NIAID
General Information
Contract Opportunity Type: Presolicitation (Original)
Original Published Date: Aug 04, 2025 08:02 pm EDT
Original Response Date: Aug 14, 2025 03:00 pm EDT
Inactive Policy: 15 days after response date
Original Inactive Date: Aug 29, 2025
Initiative: None

Classification
Original Set Aside:
Product Service Code: Q301 - REFERENCE LABORATORY TESTING
NAICS Code: 541380 - Testing Laboratories and Services

Place of Performance: MD 20852 USA

Documents

 Tender Notice

SOW-NIAID-CSP-Long-Read-Genome-20250501.docx